Sunovion (United Kingdom)
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Sunovion (United Kingdom), United Kingdom, covering academic research published from 2000 to 2023. Read More.
Open Access Percentage
45%
Total
Publications
180
Total Open
Publications
81
Total
Citations
4K
Open Access
Percentage
45%
Total
Publications
180
Total Open
Publications
81
Total
Citations
4K
Breakdown
Publisher Open
19%
Both
19%
Other Platform Open
7%
Closed
55%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 10%
7
Hybrid 31%
21
No Guarantees 59%
40
Other Platform Open
Domain 83%
39
Institution 15%
7
Other Internet 13%
6
Public 11%
5
Preprint 4%
2
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 40 |
Europe PMC | Domain | 21 |
Semantic Scholar | Public | 5 |
University of Leeds, The University of Sheffield, University of York - White Rose Research Online | Institution | 3 |
Unknown Repository | Other Internet | 2 |
University of Edinburgh - Edinburgh Research Explorer | Institution | 2 |
University College London - UCL Discovery | Institution | 2 |
Research Square | Preprint | 2 |
Radboud University - Radboud Repository | Institution | 2 |
INFN Catania - INFM-OAR | Other Internet | 2 |